2026 Best of Show Entries

2bind’s Quick ‘n’ Tidy Buffer Screen introduces a new way to approach biologics formulation by combining intelligent design with experimental efficiency. It is built for scientists who want to explore formulation space systematically and uncover how key variables such as pH, ionic strength, and excipients influence molecular stability, both individually and in combination.

At the core of this solution is an AI- and Design of Experiment inspired buffer plate featuring 96 precisely defined conditions. This setup enables a structured and comprehensive exploration of stability landscapes, allowing the identification of critical factors and their interactions in a streamlined workflow. It transforms what is often a trial-and-error process into a data-driven strategy.

The Quick ‘n’ Tidy Buffer Screen integrates seamlessly with a broad range of analytical readouts, enabling both rapid screening and in-depth characterization within the same framework. Initial insights into thermal stability and aggregation propensity can be obtained within days using Tm and Tagg measurements, allowing fast prioritization of promising conditions. After storage under defined conditions for any desired duration, samples can be subjected to techniques such as DLS, SEC-MALS, and IEX, as well as functional assays. This workflow supports both early-stage screening and detailed stability assessment, providing a continuous path from quick insights to deep understanding.

More than identifying suitable storage conditions, this platform provides clear guidance on which formulation parameters to adjust and why. It reveals your molecule’s specific requirements and defines the stability that can be achieved under optimal conditions, enabling smarter decisions and accelerating development.

"FETA (Fc-enabled T-cell Activator) is Ab Studio's proprietary bispecific antibody platform engineered to simultaneously engage T cells and myeloid effector cells (macrophages, NK cells) through a single therapeutic molecule. The platform represents a mechanistic advancement in T-cell engager (TCE) design by leveraging Fc-mediated immune activation alongside CD3-directed T-cell recruitment.

Platform Mechanism

Dual Immune Engagement (Ab Studio, 2024, Corporate Materials):

T-cell arm: CD3-binding domain recruits and activates cytotoxic T lymphocytes (CTLs)

Tumor-targeting arm: Binds disease-associated antigen (e.g., CD20, PD-L1, tumor-associated antigen)

Fc region: Retains full or enhanced Fc effector function, enabling:

Antibody-dependent cellular cytotoxicity (ADCC) via NK cells and macrophages

Antibody-dependent cellular phagocytosis (ADCP) via macrophages

Complement-dependent cytotoxicity (CDC) via classical complement pathway

Clinical Validation: GB261 (CND261)

Lead Program (Ab Studio, 2024; Cai et al., 2021, Antibody Therapeutics):

Target: CD20/CD3 bispecific T-cell engager

Design: Computationally designed and bench-validated by Ab Studio; out-licensed to Genor Biopharma (2019)

Clinical Status:

Phase II data in B-cell non-Hodgkin lymphoma (B-NHL) with encouraging efficacy and safety

Licensed to Candid Therapeutics (September 2024) for autoimmune disease development

Phase I ongoing in autoimmune indications

Significance: World's first TCE designed with the FETA platform (Ab Studio, 2024, Corporate Materials)"

"The Amperia™ Tagged Protein Quantification Kit | His-tag (AK-His-004) is an innovative, ready-to-use solution for quantifying His-tagged proteins in recombinant protein research, screening, and development.

His-tags are among the most widely used affinity tags in protein and antibody engineering, underpinning purification and detection across various expression systems. Quantification has traditionally relied on ELISA, gels, or spectrophotometric assays, which are time-consuming, variable, and poorly suited to crude samples. These bottlenecks slow decision-making in construct evaluation, expression optimisation, and therapeutic protein development.

Designed for use with Abselion’s accessible protein quantification system, Amperia, the novel kit combines antibody technology with redox electrochemical detection. It introduces electrochemical sensor strips pre-coated with GenScript’s THE™ His-tag Monoclonal Antibodies, recognised for their strong affinity and compatibility across common tag formats to reduce preparation steps and improve consistency in assay setup. Combined with Amperia’s guided, software-controlled workflow, the kit enables reproducible measurement of His-tagged proteins directly from crude or purified samples. The premix competition assay format further simplifies operation, ensuring robust results without specialist training or complex optimisation.

Each kit contains pre-coated sensor strips, assay plates, matched detection reagents, and buffers — providing a complete, practical package for reliable His-tag protein quantification.

[What’s new] 

This is one of the first affinity-based, electrochemical, automated kits for crude samples. It extends Amperia beyond antibody and AAV analysis into recombinant protein workflows. Simplifying the quantification of a universal affinity tag introduces an enabling tool for protein and antibody engineering, supporting faster screening, more confident process optimisation, and better decision-making across.

https://www.abselion.com/assay-kits

https://www.abselion.com/enabling-his-tagged-protein-analysis-in-expression-workflows/

"Corynex® and AJICAP®: Advancing Scalable, Next-Generation Biologics and Conjugates 

 

Corynex® and AJICAP® are proprietary platform technologies from Ajinomoto Bio-Pharma Services that address critical challenges in biologics production and bioconjugation, delivering improved manufacturability, scalability, and precision. 

Corynex® is a microbial expression system based on Corynebacterium glutamicum that enables high-yield production of long peptides, VHHs, and antibody mimetics. By secreting endotoxin-free, correctly folded proteins directly into the culture medium, Corynex® simplifies purification and increases efficiency. Recent advancements expand its utility beyond expression: Corynex® now offers conjugation-ready VHHs for applications including radiopharmaceuticals and LNP conjugation, leveraging engineered cysteines and non-canonical amino acid (ncAA) incorporation for rapid, clean click-chemistry attachment. Additionally, To enable half‑life extension and precise pharmacokinetic control, Corynex® harnesses XL‑protein’s PAS polymers and delivers high‑efficiency production of PASylated proteins 

AJICAP® is a site-specific antibody conjugation and linker technology that enables homogeneous ADCs and next-generation drug conjugates with precise control of drug-to-antibody ratio (DAR), without antibody engineering or enzymes. Recent upgrades enable fully controlled DAR, including precise DAR1 conjugates with oligonucleotides, LNPs, and HAPI payloads, while maintaining high reproducibility and scalability. 

Corynex® and AJICAP® provide powerful, integrated platforms to accelerate the development and manufacturing of next-generation therapeutics with enhanced precision, flexibility, and clinical potential.

"Amazon Bio Discovery is a new AI-powered application that gives scientists direct access to AI biology models for antibody discovery and optimization. Whether you are a computational biologist building reusable workflows or a bench scientist running experiments, agentic assistants help you select the right models, optimize inputs, and evaluate candidates without requiring coding or infrastructure management. 

Integrated wet-lab partners handle synthesis and testing, and results automatically route back for analysis and model refinement, creating a continuous lab-in-the-loop experimentation cycle that accelerates the Design-Build-Test-Learn (DBTL) workflow from months to weeks.

The application features a catalog of 40+ AI biology models with wet-lab validated benchmarks built in partnership with the Gray Lab using the largest and most diverse antibody datasets in public literature. Scientists can bring and train their own proprietary models, refining predictions each cycle with newly generated experimental data. An integrated CRO network enables direct ordering of sequences, expression, and binding assays with transparent pricing and turnaround times, eliminating experimental data silos.

Released on April 14, 2026, Amazon Bio Discovery introduces agentic assistants that make advanced AI biology models accessible to both computational and non-computational researchers, Pareto-based multi-objective optimization for candidate selection, and a unified application that bridges computational predictions with wet-lab validation. Validated with Memorial Sloan Kettering Cancer Center, the application was used to design nearly 300,000 novel antibody molecules, compressing what traditionally takes up to a year into weeks. Built on AWS infrastructure with enterprise-grade security, outcome-based pricing, and full data isolation, proprietary data and IP remain protected.

"Stop Re-Engineering. Start Expressing.

Complex engineering shouldn't stand between your sequences and the clinic. ATUM’s Lock-In™ Bispecific Platform is engineered to bypass the traditional bottlenecks of multi-specific development.

The Lock-In™ Advantage:

Precision: Zero light chain mispairing.

Performance: Potency & binding that mirror your original sequences.

Scalability: High-yield expression with a ""developability-first"" design.

Freedom to Operate: No upfront access fees. No royalties.

Visit Booth 205 to see our developability data or view our poster to learn how Lock-In™ can accelerate your path to IND.

"Modern antibody discovery is defined by increasing formats, data volume, and AI. Discovery teams are now routinely working with a growing constellation of multispecific formats – and the tools they rely on haven't kept up. Most organizations are still registering sequences manually, in systems with no structural understanding of antibodies, no way to keep pace with format innovation, and no path from sequence data to experimental data to ML-ready datasets.

Benchling Biologics is built to change that. It introduces a first-class protein concept with 2D structural awareness: domains assembled into chains, informed by a format, and rendered in an interactive glyph. We're establishing an industry-standard nomenclature: a data model based on AbML and format design based on VERITAS. Any format a team works with, from mAbs to complex multispecifics and fusion proteins, can be defined without writing a line of code.

Registration is designed for scale, supporting 1000 antibodies and all of their component sequences at once, starting from full-length chains or domains. Benchling automatically detects domains; annotates CDRs, frameworks, liabilities, and mutations; and validates biological correctness.

The result is the AI infrastructure antibody teams have been missing: a biologically meaningful data model so proteins are captured accurately and completely, ready for analysis and model training from day one. Benchling Biologics is native to Benchling's R&D platform, where teams already document experiments, run workflows, and capture assay data. In Benchling, every protein is surrounded by full experimental context, powering the antibody design-build-test-learn loop at scale.

At Biointron, we offer the flexibility to rapidly express large quantities of antibodies at varying scales using HEK293 or CHO cells, both known for their efficiency in recombinant protein expression. We also integrate our recombinant protein service to enhance antibody expression workflows, ensuring optimized outcomes for a wide range of research and therapeutic applications. This enables us deliver high quality antibodies with low endotoxin levels (<1EU/mg) and high purity (>95% by SDS-PAGE).

Vega is the world's first and only 48-channel SPR biosensor platform. It is the fastest, most powerful and flexible SPR platform available and enables label-free SPR and industry-leading ultra-high-throughput screening for fragment and small molecule workflows with minimal sample use. For large molecule assays, Vega delivers analyte screening in high throughput, and delivers up to 48 x 48 epitope binning and the ability to measure 1,152 kinetic variants unattended (ligand screening). Vega comes with an optional robot enabling up to 5 stacks of plates unattended to screen >20,000 assays in a 24-hour period. 

"Our chemical protein synthesis platform provides rapid and precise access to complex biologics, including peptides, therapeutic proteins, antibody fragments (e.g. VHH, scFv) and fully customized protein constructs. This technology enables the production of highly defined biomolecules that are difficult or impossible to obtain using conventional recombinant expression systems.

Unlike traditional biologics manufacturing, our approach allows full control at the amino acid level, enabling the site-specific incorporation of non-natural amino acids, conjugation handles (e.g. fluorophores, PEG, chelators, click chemistry moieties), and homogeneous post-translational modifications. This ensures batch-to-batch consistency, high purity, and structural homogeneity.

What is new in this release:

This latest development expands our capabilities to larger and more complex protein formats (up to ~400 amino acids), including engineered antibody fragments and multifunctional biologics designed for targeted therapies, radiopharmaceuticals, and advanced diagnostics. We have also enhanced our conjugation toolbox, allowing precise positioning of payloads for applications such as antibody-drug conjugates (ADCs) or radiolabeled proteins.

Technical specifications:

- Protein/peptide length: up to ~400 amino acids

- High purity (>95%), endotoxin-free

- Site-specific modifications and conjugation

- Support for non-natural amino acids and complex structures

- Scalable from R&D to GMP production

- Fast turnaround times compared to recombinant systems

This platform offers a powerful alternative to biologics production, accelerating early discovery, enabling innovative designs, and reducing development risks for next-generation therapeutics.

"Introducing the next-generation Biacore™ 8 series SPR systems; high-throughput instruments designed for hands-off, automated discovery. They combine high sensitivity and flexible workflows to support a wide range of molecular interactions, from early discovery through development.

Integrated plate handling and flexible workflows reduce hands-on time while supporting rapid screening and high-quality characterization across molecular modalities. With up to 72 hours of unattended runtime, 16 flow cells, and scalable configurations, Biacore 8S and Biacore 8S+ systems accelerate confident decisions and are built to evolve with your needs in discovery today and for the innovations of tomorrow. Future-ready SPR for a fast-moving world.

Accelerate discovery with speed, scalability and sensitivity.

PeptiNanodisc is DIMA Biotech's newly developed product for delivering high quality, full-length recombinant membrane proteins in a detergent-free and lipid-free format. It provides stable, soluble membrane proteins that retain native-like structure and activity, making them ready for immediate use in downstream applications. Traditional methods rely on detergents for membrane protein solubilization, which can compromise protein stability and function. Lipid-based nanodisc systems offer an alternative but may introduce unwanted membrane interactions, particularly in cell-based assays. PeptiNanodisc overcomes these limitations by using specially engineered synthetic peptides to replace both detergents and lipids. Following mild detergent extraction, these peptides shield hydrophobic transmembrane regions, resulting in purified membrane proteins that remain stable in solution without the need for lipids. What is new in this product is its fully lipid-free design, which significantly reduces the risk of membrane fusion and assay interference. This makes PeptiNanodisc particularly well-suited for cell-based functional assays, drug screening, and signaling studies. The product is compatible with a wide range of membrane protein targets, regardless of size or complexity. PeptiNanodisc offers a reliable and user-friendly solution for researchers seeking functional membrane proteins with improved stability and assay performance.

"DPBIO is a pioneering innovator based in California, specializing in high-throughput droplet microfluidic technology and providing cutting-edge life science solutions to researchers and industry leaders worldwide.

At DPBIO, we integrate advanced microfluidic technology with life sciences to develop comprehensive solutions, including microfluidic chips, instruments, and reagents. Our flagship products—such as the CytoSpark® High-throughput Screening System, OMNIdrop System—empower scientists in antibody discovery, enzyme evolution, strain screening, small-molecule drug screening, cancer research, early disease detection, viral quantification, and biopharmaceutical quality control.

Trusted by leading biotech and pharmaceutical companies, top-tier research institutions, and clinical laboratories worldwide, DPBIO is committed to advancing life sciences with high-performance analytical and detection systems. Our mission is to accelerate drug discovery, synthetic biology, biomedical research, and precision medicine, driving breakthroughs that transform life science innovation."

"The AbNano® Anti-NK-Cell VHH Library is a naturally derived, immune-focused single-domain antibody library designed to accelerate discovery of VHH binders against native NK-cell surface targets. It supports rapid hit identification in research, diagnostic, and early therapeutic discovery workflows.

Product Description

The AbNano® Anti-NK-Cell VHH Library is an immune-derived single-domain antibody (sdAb) library constructed from camelid heavy-chain-only antibodies (VHH domains) via target-focused immune selection. Built on the proven AbNano VHH platform, this library facilitates identification of high-affinity binders to native NK-cell surface antigens and complex membrane proteins more efficiently than synthetic approaches.

The AbNano® Anti-NK-Cell VHH Library exhibits frameworks homologous to human VH3 and CDR3 length distributions comparable to human IgHV3 germline genes, reducing immunogenicity risks and simplifying humanization for therapeutic applications. 

Library Construction and Quality Control 

More than 2 × 107 PBMCs were collected and processed using our proprietary workflows for RNA isolation, cDNA synthesis, and PCR amplification. Transformants were screened and validated by Sanger and next-generation sequencing, with 79% of VHH sequences in-frame. V-gene representation from the camelids showed 99.89% of NGS reads mapping to IGHV3, with the remaining 0.11% of sequences mapping to IGHV1 (0.013%) and IGHV4 (0.09%). 

Technical Specification

• Source Species: Llama

• Immunogen: Human NK-Cells

• Library Size: 2.5 × 109 CFU

• Delivery Format: Monovalent Phage-Displayed VHH Library

• Discovery Workflow: Solid-phase and solution-phase panning.

This library supports phage display-based screening workflows for rapid hit identification against NK-cell epitopes in research, diagnostics, and early therapeutic discovery.

"Gator Plus+ is Gator Bio’s next-generation biolayer interferometry platform, built to deliver high-quality kinetic and binding data with the speed, flexibility, and reproducibility modern discovery teams need. Designed for medium-throughput workflows, its 8-channel format supports quantitation of 456 samples in one uninterrupted run, 16x16 epitope binning, and kinetic characterization in a compact, easy-to-use benchtop system that helps scientists move from assay setup to actionable results faster.

What makes Gator Plus+ especially valuable is the balance it strikes between performance and versatility. Its compatibility with both 96- and 384-well plates, stable baseline, high-resolution readout, and expanded thermal control range from 10°C to 40°C make it well suited for a wide range of applications, including antibody screening, assay development, and small molecule analysis. This broader thermal range gives users greater flexibility to optimize assay conditions and support more demanding experimental requirements. For precious samples, the 10°C assay temperature and 40 µL sample volume minimizes consumption and preserves integrity, facilitating sample recovery and reuse.

By enabling reliable label-free analysis without sacrificing usability, Gator Plus+ helps teams accelerate decision-making while maintaining the data confidence required in demanding R&D environments. For end users, it means a platform that can support everyday workflows as well as more advanced binding studies, while improving data confidence and operational efficiency.

GENEWIZ Launches Gene Synthesis 2.0 at PEGS 2026

GENEWIZ is unveiling Gene Synthesis 2.0 at PEGS 2026, a next-generation platform designed to accelerate and simplify the ordering of high-quality custom gene sequences.

Built around three flexible packages - Sprint, Flex, and Flex+ - Gene Synthesis 2.0 delivers a streamlined, intuitive ordering experience with expanded vector capabilities and upgraded AI/ML-powered codon optimization. Researchers can easily design, select, and onboard constructs, moving from sequence to order in just minutes.

What’s New in Gene Synthesis 2.0:

Sprint / Flex / Flex+

• Sprint: Simple constructs in as fast as 5 business days, ideal for protein engineering and antibody discovery

• Flex / Flex+: Full design flexibility for any sequence; Flex+ offers expedited delivery for time-critical projects

Enhanced Ordering Experience

• New, intuitive ordering interface with an expanded vector library

• Access to expanded GENEWIZ, shared, and custom vectors, with the ability to onboard new vectors - all in one place

Advanced Codon Optimization

• AI/ML-powered engine combining heuristic methods with deep learning

• Trained on high-expression datasets for stronger, more reliable expressions

• Demonstrated performance advantage over commercial tools for antibody constructs (learn more Thursday morning at Poster C053)

Built on GENEWIZ’s long-standing expertise in synthesizing complex sequences, Gene Synthesis 2.0 continues to deliver industry-leading success rates for even the most challenging constructs, while now also enabling faster turnaround for simpler designs. This allows researchers to seamlessly scale from rapid screening to complex construct development, all within a single, unified platform.

"The TurboCHO™ Protein Expression Kit is a next-generation CHO-based transient expression system engineered to deliver speed, high yield, and reproducible protein quality for antibody discovery and development. Built on a newly developed, engineered TurboCHO™ CHO-K1 cell line, the kit provides a fully integrated solution including cell line, optimized expression medium, and transfection reagents, enabling streamlined and consistent in-house protein production.

Designed to address key bottlenecks in biologics workflows, TurboCHO™ enables recombinant protein expression in as little as 3–7 days, significantly accelerating traditional CHO timelines, compared to market-leading products, while achieving high titers and consistent product quality suitable for downstream functional, biophysical, and developability assays. The platform supports a broad range of modalities, including monoclonal antibodies, bispecifics, and other complex formats.

The system is optimized for high-throughput workflows, supporting plate-based expression and seamless scale-up to shake flasks and bioreactors without re-optimization. This ensures reproducible performance across scales, reducing development risk and accelerating decision-making.

The TurboCHO™ Protein Expression Kit brings GenScript’s 25 years of protein expression expertise into the research lab. As a brand‑new kit solution, it combines speed, productivity, and consistent quality to accelerate biologics discovery with confidence.

In AI-driven protein and antibody design, advantage comes from iteration speed and the quality of biology-native data. ALiCE HTPE enables the production of full-length, folded, functional proteins within 24 hours—compressing timelines versus traditional cell-based systems and reducing the latency between computational design and wet-lab validation. Compared to other cell-free systems, ALiCE HTPE supports complex molecules with eukaryotic characteristics that cannot be produced otherwise. Using ALiCE HTPE unlocks a new level of speed and capability for discovery teams!

"MaxCyte’s ExPERT DTx™ is a high-throughput electroporation platform designed to enable efficient, scalable, and reproducible delivery of nucleic acids and other molecules into a wide range of cell types. Particularly well-suited for protein production workflows, The DTx™ supports rapid, consistent transfection to accelerate expression screening, optimization, and cell line development. Built on MaxCyte’s clinically validated flow electroporation technology, the system delivers high cell viability and reproducible performance across research and early development applications, including protein production and cell therapy.

New in this release, the ExPERT DTx introduces a 96-well, high-throughput format capable of processing up to 96 samples in minutes, significantly increasing screening speed and experimental throughput. The platform enables customizable, well-by-well parameter control, allowing scientists to optimize conditions with precision and reduce variability across experiments—critical for protein production consistency. Enhanced software and workflow integration support streamlined experiment design and compatibility with automated lab environments.

DTx is also designed to bridge discovery and development, with protocols that can be transferred to MaxCyte’s GMP-compliant platforms without reoptimization, helping reduce risk and accelerate scale-up.

For PEGS attendees, ExPERT DTx offers a powerful solution to improve throughput, reproducibility, and scalability in protein production and cell-based workflows—enabling faster, more confident progression from screening to development.

https://platforma.bio

Platforma is an end-to-end biologics discovery solution from NGS data to therapeutic assets, built for high-performance R&D teams. Since we've launched last year, we've launched solutions for in vitro and in vivo antibody discovery, translational immune research, and multiomics analysis. Our latest releases include integration of single-cell data against deep bulk repertoires to identify rare but highly expanded clones, and clustering based on predicted 3D structures and paratopes to group candidates by true functional epitopes.

"An antibody screening service that streamlines the transition from antibody hit generation to lead selection. It is intended for AI/ML-driven antibody discovery groups generating large IgG candidate sets, where the main challenge is rapid triage prior to committing to costly and resource-intensive assays. This service converts these AI-generated or in silico libraries into early experimental binding data before downstream mammalian expression and scale-up.

The workflow is based on automated, multiplex expression and screening. A 96-plex full-length IgG screen expresses variants in parallel and generate binary expression and binding readouts across the full set, enabling early identification of non-binders. Top performing candidates are taken forward for SPR (surface plasmon resonance) analysis.

Key capabilities:

- End to end antibody triage as a service, from DNA to binding data

- 96-plex full-length IgG expression

- Binary binding assessment to rapidly identify non-binders

- Focused SPR validation on prioritized candidates

OPM-293 CD05 Medium and its companion OPM-293 ProFeed are formulated to enhance protein production in HEK293 suspension cultures. Both are chemically defined and free of animal-derived components, supporting consistency and regulatory compliance.

When used together for secreted protein expression, this system can achieve titers exceeding 1 g/L. In addition to standard HEK293 cells, the medium and feed are compatible with other 293-derived cell lines, including Expi293 and Expi293 Pro, offering flexibility across different workflows.

Partillion Bioscience’s Nanovial Developer Kits open Partillion’s Nanovial reagents and validated cell capture antibodies to researchers building custom functional assays for antibody discovery, cell therapy, immuno-oncology, and cell line development. Rather than limiting users to a fixed kit format, Developer Kits let researchers choose the Nanovial size and cell capture antibodies that best fit their cells, targets, and workflow.

Built on Partillion’s hydrogel Nanovial platform, the kits support both single-cell and multicell applications. For example, antibody discovery teams can use Nanovial Developer Kits to build custom functional antibody library screening workflows. A team developing agonist, antagonist, bispecific, or cell-engaging antibodies could pair an antibody-producing CHO cell with a Jurkat reporter or target cell in a Nanovial-based multicell assay, then screen for functional activity such as reporter activation, immune-cell engagement, cytokine secretion, or target-cell killing.

By providing modular access to validated Nanovial reagents and capture antibodies, Developer Kits let pharma researchers design assays around their own targets and therapeutic mechanisms while reducing reagent optimization and accelerating functional readouts. Options are available for human, mouse, and CHO cell workflows, making the kits relevant across discovery, translational research, and biologics development.

The Lumit® FcγR Binding Immunoassays are novel competition assays to measure the interaction between human Fc receptors and antibodies or Fc fusion proteins.  Lumit® FcγR Binding assays are based on a split luciferase technology that offer a quick, simple, no-wash alternative to ELISAs to be used for antibody discovery and under GMP conditions for biologics manufacturing applications. We’re introducing a full repertoire of Lumit® assays for Fc receptor characterization:  FcγRI, FcγRIIa (H131), FcγRIIa (R131), FcγRIIIa (V158), FcγRIIIa (F158), FcγRIIb, and FcγRIIIb to provide a thorough understanding of your antibody's potential immune effector function, aiding in the optimization of therapeutic antibodies for desired clinical outcomes. 

"First Look Assay is a newly introduced comparative screening offering from Single Cell Technology designed to support early decision-making before a full single-B antibody discovery campaign. This new offering allows teams to compare up to 4 samples per run and determine both whether to move forward with discovery and which sample is the strongest starting point.

The assay is performed on small aliquots of frozen cells and uses AbTheneum cell isolation and antibody screening to run samples in parallel under the intended assay plan. Candidate inputs can include different species, tissue sources, cohorts, immunization strategies, animal strains, or cell enrichment approaches. Because antibodies are not sequenced in First Look, the study remains lower cost and faster to execute while still providing meaningful single-cell readouts for each sample.

Technical outputs include:

-single-cell hit rate

-screening profile under the assay plan

-comparative performance across samples

-projected hit count for a full-scale campaign

First Look helps teams do two things before committing larger resources: (1) select the strongest sample for a full AbTheneum single-B antibody discovery campaign, or (2) use comparative sample data to justify moving forward with that campaign at all. This gives developers a practical way to reduce uncertainty, de-risk assay plans, and make better-supported go/no-go decisions before full discovery.

"AffinEx Protein A cartridges are designed for monoclonal antibody purification through affinity capture. Purification of mAb from cell culture with Affinex Protein A cartridges delivers high yield with high purity via a fast, scalable and automatable workflow.   

Optimized for Resolvex positive pressure workstations, AffinEx is offered in many formats which provides scalable automation for mAb purification with a series of cartridges and well-plates offering consistent results.

AffinEx Protein A is a unique sorbent that is stable under dry conditions providing logistical and economic benefits. AffinEx may be reused after alkaline cleaning and renewal without losing binding capacity. Additionally, AffinEx is stable under ambient conditions for up to 24 months.

"The Gibco™ CHOvantage™ GS Cell Line Development Kit provides a complete, end-to-end solution for cloning and expressing recombinant proteins in CHO-derived suspension cultures. Designed for ease of use, the kit combines all the essential components for transfection, expression, clone generation, and stable cell line selection in one kit.

Featuring cGMP CHO-K1 GS cells and an advanced transposon vector system, the kit is optimized with the Efficient-Pro™ family of media to support robust cell growth and protein production. With streamlined workflows, it enables researchers to achieve high titers while also offering simplified commercial licensing options to accelerate development from research to commercialization.

Technology foundation:

•cGMP-banked CHO-K1 GS knockdown host cell line

•Transposon-based vector system for consistent gene integration

•Gibco™ Efficient-Pro™ media and feeds

CHOvantage™ Kit benefits

•High, consistent productivity

•Monoclonal antibody (mAb) titers ≥7 g/L

•Fc fusion proteins and bispecific antibodies (bsAb) ≥5 g/L

•Accelerated development timelines

•Stable pools generated in as little as ~4 weeks

•Rapid progression from transfection to stable clones

•Robust, long-term stability

•Demonstrated clonal stability up to 100 generations

•Simplified, flexible licensing

•Research license included with kit purchase

•Royalty-free, milestone-free commercial licensing options

"The Gibco™ Expi293™ PRO Expression System is a next-generation, fully integrated expression system engineered to push the boundaries of transient protein production. Built on an advanced HEK293 platform, it delivers exceptional yields across a broad range of proteins, including challenging and low-expressing targets, while maintaining most native folding and post-translational modifications. Designed for speed, scalability, and simplicity, the Expi293 PRO system includes high-density HEK293 suspension cells, chemically defined, animal origin–free medium, and an optimized transfection kit that work together to maximize cell density, transfection efficiency, and protein yield. With rapid expression kinetics, the Expi293 PRO system enables protein production in as little as 2–4 days, significantly accelerating timelines for discovery and development. The system routinely achieves multi-fold increases in yield compared to previous-generation 293 systems, with titers reaching up to ~5 g/L, making it one of the highest-performing transient expression platforms available. The Expi293 PRO system is also designed for flexibility across workflows, from high-throughput screening in automated formats to scalable production from milliliter to multi-liter volumes. Its streamlined, automation-friendly protocol reduces hands-on time, reagent consumption, and plastic waste, enabling more efficient and sustainable protein production.

 

 Key technical specifications: 

• HEK293-derived, high-density suspension cell line

• Chemically defined, serum-free, animal origin–free medium

• Transient, lipid-based high-efficiency transfection kit

• Protein yields up to ~5 g/L

• Rapid expression: protein in 2–4 days

• Scalable from <1 mL to >10 L; automation compatible

 

The Expi293 PRO Expression System empowers scientists to unlock previously inaccessible protein targets with unmatched speed, yield, and reliability.

The core of SMab™ platform lies in the modern immunological technology combined with cell sorting technology to screen single antibody-secreting cells (B lymphocytes) from immunized animals, and then amplify the antibody-coding genes obtained using modern molecular biology techniques. Thereby producing genetically engineered monoclonal antibodies with market value through large-scale in vitro expression.